Terry Hyslop

Positions:

Professor of Biostatistics & Bioinformatics

Biostatistics & Bioinformatics
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 2001

Temple University

Grants:

Combined breast MRI/biomarker strategies to identify aggressive biology

Administered By
Integrative Genomics
Role
Principal Investigator
Start Date
End Date

Combined breast MRI/biomarker strategies to identify aggressive biology

Administered By
Medicine, Medical Oncology
Awarded By
National Institutes of Health
Role
Biostatistician
Start Date
End Date

Tension-Stat3-miR-mediated metastasis

Administered By
Medicine, Medical Oncology
Awarded By
University of California, San Francisco
Role
Biostatistician
Start Date
End Date

Smartphone Enabled Point-of-Care Detection of Serum Markers of Liver Cancer

Administered By
Biomedical Engineering
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Smartphone Enabled Point-of-Care Detection of Serum Markers of Liver Cancer

Administered By
Biomedical Engineering
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Publications:

Racial differences in Helicobacter pylori antibody prevalence by year of birth and demographic factors in a consortium of US adults

Authors
Varga, MG; Butt, J; Blot, WJ; Le Marchand, L; Haiman, C; Chen, Y; Wassertheil-Smoller, S; Ho, GYF; Tinker, LE; Peek, RM; Potter, JD; Cover, TL; Hendrix, L; Hyslop, T; Zeleniuch-Jacquotte, A; Berndt, S; Hildesheim, A; Waterboer, T; Pawlita, M; EPPlein, M
URI
https://scholars.duke.edu/individual/pub1415374
Source
wos
Published In
Helicobacter
Volume
24
Published Date

Baseline Colonoscopy Findings Associated With 10-Year Outcomes in a Screening Cohort Undergoing Colonoscopy Surveillance.

BACKGROUND & AIMS: Few studies have evaluated long-term outcomes of ongoing colonoscopic screening and surveillance in a screening population. We aimed to determine the 10-year risk for advanced neoplasia (defined as adenomas ≥10mm, adenomas with villous histology or high-grade dysplasia, or colorectal cancer [CRC]) and assessed whether baseline colonoscopy findings were associated with long-term outcomes. METHODS: We collected data from the Department of Veterans Affairs Cooperative Studies Program Study on 3121 asymptomatic veterans (50-75 years old) who underwent a screening colonoscopy from 1994 through 1997 at 13 medical centers and were then followed for 10 years or until death. We included 1915 subjects with at least 1 surveillance colonoscopy and estimated cumulative incidence of advanced neoplasia by Kaplan-Meier curves. We then fit a longitudinal joint model to estimate risk of advanced neoplasia at each subsequent examination after baseline, adjusting for multiple colonoscopies within individuals. RESULTS: Through 10 years of follow-up, there were 146 individuals among all baseline colonoscopy groups found to have at least 1 incident advanced neoplasia. The cumulative 10-year incidence of advanced neoplasia was highest among those with baseline CRC (43.7%; 95% CI 13.0%-74.4%), followed by those with baseline advanced adenoma (AA) (21.9%; 95% CI 15.7-28.1). The cumulative 10-year incidence of advanced neoplasia was 6.3% (95% CI 4.1%-8.5%) and 4.1% (95% CI 2.7%-5.4%) for baseline 1 to 2 small adenomas (<1cm, and without villous histology or high-grade dysplasia) and no neoplasia, respectively (log-rank P = .10). After adjusting for prior surveillance, the risk of advanced neoplasia at each subsequent examination was not significantly increased in veterans with 1 or 2 small adenomas at baseline (odds ratio 0.96; 95% CI 0.67-1.41) compared with veterans with no baseline neoplasia. CONCLUSIONS: Baseline screening colonoscopy findings associate with advanced neoplasia within 10 years. Individuals with only 1 or 2 small adenomas at baseline have a low risk of advanced neoplasia over 10 years. Alternative surveillance strategies, could be considered for these individuals.
Authors
Lieberman, D; Sullivan, BA; Hauser, ER; Qin, X; Musselwhite, LW; O'Leary, MC; Redding, TS; Madison, AN; Bullard, AJ; Thomas, R; Sims, KJ; Williams, CD; Hyslop, T; Weiss, D; Gupta, S; Gellad, ZF; Robertson, DJ; Provenzale, D
MLA Citation
Lieberman, David, et al. “Baseline Colonoscopy Findings Associated With 10-Year Outcomes in a Screening Cohort Undergoing Colonoscopy Surveillance.Gastroenterology, vol. 158, no. 4, Mar. 2020, pp. 862-874.e8. Pubmed, doi:10.1053/j.gastro.2019.07.052.
URI
https://scholars.duke.edu/individual/pub1402475
PMID
31376388
Source
pubmed
Published In
Gastroenterology
Volume
158
Published Date
Start Page
862
End Page
874.e8
DOI
10.1053/j.gastro.2019.07.052

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

BACKGROUND: Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone receptor-positive patients with metastatic breast cancer have thus far shown conflicting results. PATIENTS AND METHODS: We pooled data from two similar phase III randomised trials of ET ± Bev (LEA and Cancer and Leukemia Group B 40503) to increase precision in estimating treatment effect. Primary end-point was progression-free survival (PFS). Secondary end-points were overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety. Exploratory analyses were performed within subgroups defined by patients with recurrent disease, de novo disease, prior endocrine sensitivity or resistance and reported grades III-IV hypertension and proteinuria. RESULTS: The pooled sample consisted of 749 patients randomised to ET or ET + Bev. Median PFS was 14.3 months for ET versus 19 months for ET + Bev (unadjusted hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.66-0.91; p < 0.01). ORR and CBR with ET and ET + Bev were 40 versus 61% (p < 0.01) and 64 versus 77% (p < 0.01), respectively. There was no difference in OS (HR 0.96; 95% CI 0.77-1.18; p = 0.68). PFS was superior for ET + Bev for endocrine-sensitive patients (HR 0.68; 95% CI 0.53-0.89; p = 0.004). Grade III-IV hypertension (2.2 versus 20.1%), proteinuria (0 versus 9.3%), cardiovascular (0.5 versus 4.2%) and liver events (0 versus 2.9%) were significantly higher for ET + Bev (all p < 0.01). Hypertension and proteinuria were not predictors of efficacy (interaction test p = 0.33). CONCLUSION: The addition of Bev to ET increased PFS overall and in endocrine-sensitive patients but not OS at the expense of significant additional toxicity. TRIALS REGISTRATION: ClinicalTrial.Gov NCT00545077 and NCT00601900.
Authors
Martín, M; Loibl, S; Hyslop, T; De la Haba-Rodríguez, J; Aktas, B; Cirrincione, CT; Mehta, K; Barry, WT; Morales, S; Carey, LA; Garcia-Saenz, JA; Partridge, A; Martinez-Jañez, N; Hahn, O; Winer, E; Guerrero-Zotano, A; Hudis, C; Casas, M; Rodriguez-Martin, C; Furlanetto, J; Carrasco, E; Dickler, MN; GEICAM Spanish Breast Cancer Group,; GBG (German Breast Group),; Alliance for Clinical Trials in Oncology (Alliance),
URI
https://scholars.duke.edu/individual/pub1395967
PMID
31276981
Source
pubmed
Published In
Eur J Cancer
Volume
117
Published Date
Start Page
91
End Page
98
DOI
10.1016/j.ejca.2019.06.002

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.

Notwithstanding the positive clinical impact of endocrine therapies in estrogen receptor-alpha (ERα)-positive breast cancer, de novo and acquired resistance limits the therapeutic lifespan of existing drugs. Taking the position that resistance is nearly inevitable, we undertook a study to identify and exploit targetable vulnerabilities that were manifest in endocrine therapy-resistant disease. Using cellular and mouse models of endocrine therapy-sensitive and endocrine therapy-resistant breast cancer, together with contemporary discovery platforms, we identified a targetable pathway that is composed of the transcription factors FOXA1 and GRHL2, a coregulated target gene, the membrane receptor LYPD3, and the LYPD3 ligand, AGR2. Inhibition of the activity of this pathway using blocking antibodies directed against LYPD3 or AGR2 inhibits the growth of endocrine therapy-resistant tumors in mice, providing the rationale for near-term clinical development of humanized antibodies directed against these proteins.
Authors
Cocce, KJ; Jasper, JS; Desautels, TK; Everett, L; Wardell, S; Westerling, T; Baldi, R; Wright, TM; Tavares, K; Yllanes, A; Bae, Y; Blitzer, JT; Logsdon, C; Rakiec, DP; Ruddy, DA; Jiang, T; Broadwater, G; Hyslop, T; Hall, A; Laine, M; Phung, L; Greene, GL; Martin, L-A; Pancholi, S; Dowsett, M; Detre, S; Marks, JR; Crawford, GE; Brown, M; Norris, JD; Chang, C-Y; McDonnell, DP
MLA Citation
Cocce, Kimberly J., et al. “The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.Cell Rep, vol. 29, no. 4, Oct. 2019, pp. 889-903.e10. Pubmed, doi:10.1016/j.celrep.2019.09.032.
URI
https://scholars.duke.edu/individual/pub1416479
PMID
31644911
Source
pubmed
Published In
Cell Reports
Volume
29
Published Date
Start Page
889
End Page
903.e10
DOI
10.1016/j.celrep.2019.09.032

Breast Cancer in Tanzanian Patients: An Assessment of Tumor Type, Grade, Biomarker status, and Tumor Infiltrating Lymphocytes

Authors
Mremi, A; Broadwater, G; Hyslop, T; Hall, A
MLA Citation
Mremi, Alex, et al. “Breast Cancer in Tanzanian Patients: An Assessment of Tumor Type, Grade, Biomarker status, and Tumor Infiltrating Lymphocytes.” Laboratory Investigation, vol. 99, NATURE PUBLISHING GROUP, 2019.
URI
https://scholars.duke.edu/individual/pub1404159
Source
wos
Published In
Laboratory Investigation
Volume
99
Published Date

Research Areas:

Breast Neoplasms
Cohort Studies
Colorectal Neoplasms
Gastrointestinal Hormones
Gastrointestinal Tract
Italy
Lung Neoplasms
Models, Statistical
Neoplasm Invasiveness
Prognosis
Socioeconomic Factors
Survival Analysis
Thyroid Neoplasms
Thyroidectomy
Urogenital System